“An Extra Variable to Consider”—Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials-Reference-Cited by-同舟云学术

“An Extra Variable to Consider”—Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials

Published:2022-02-09 Issue:5 Volume:11 Page:221-224
ISSN:2048-7207
Container-title:Journal of the Pediatric Infectious Diseases Society
language:en
Short-container-title:

Author:

Fatola Omolayo¹,Corneli Amy²³,Perry Brian²,Hanlen-Rosado Emily²,Nsonwu Adora²,Constantine Evangelia P⁴,Thompson Amelia B⁵⁶⁷

Affiliation:

1. Indiana University School of Medicine , Indianapolis, Indiana , USA

2. Department of Population Health Sciences, Duke University School of Medicine , Durham, North Carolina , USA

3. Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina , USA

4. Dartmouth College , Hanover, New Hampshire , USA

5. Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina , USA

6. Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina , USA

7. Department of Pediatrics, Division of Infectious Diseases, AdventHealth for Children , Orlando, Florida , USA

Abstract

Abstract Our study explores the understanding of vaccine-induced seropositivity (VISP) and its potential impact on US adolescents’ and caregivers’ willingness to participate in adolescent HIV vaccine clinical trials. Findings from in-depth interviews suggest that addressing concerns about VISP will be essential for future pediatric HIV vaccine trials in the United States.

Funder

National Institute of Allergy and Infectious Diseases

U.S. Public Health Service

HVTN Research and Mentorship Program

Duke University Center for AIDS Research

NIH

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,General Medicine,Pediatrics, Perinatology and Child Health

Link

https://academic.oup.com/jpids/article-pdf/11/5/221/43892389/piac001.pdf

Reference12 articles.

1. Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa.;Hosek;J Int AIDS Soc,2016

2. Progress in HIV vaccine development.;Hsu;Hum Vaccin Immunother,2017

3. Inclusion of adolescents in STI/HIV biomedical prevention trials: autonomy, decision making, and parental involvement.;Rosenthal;Clin Pract Pediatr Psychol,2018